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ABSTRACT 1 
Background 2 
Exercise testing is increasingly being used as a prognostic indicator in Cystic Fibrosis 3 
(CF) but it is reported to be underutilised in UK CF centres, particularly in children. 4 
Here, we evaluated the CPET results of our children with CF at the CF annual review 5 
and its possible clinical value.  6 
 7 
Method 8 
A pilot observational study comparing CPET results using a cycle ramp test (peak 9 
oxygen uptake - VO2peak) and pulmonary function (forced expiratory volume in 1 10 
second  W FEV1) was performed. Body mass index (BMI) was used as a marker of 11 
disease severity. Data were identified from clinical case notes and our CF database. 12 
 13 
Results  14 
Thirty-eight children (mean age 11±2.4; range 7-14 years; sex 17M: 21F) completed 15 
at least one CPET with 95% achieving technically satisfactory tests allowing 16 
measurement of VO2peak. Mean VO2peak was 105±18; range 74 - 150 % predicted with 17 
8 % of children having a reduced VO2peak of < 85 % of predicted. Mean FEV1 z-score 18 
was -0.77±1.24, range -4.42  W 2.24. We did not demonstrate a significant correlation 19 
between VO2peak and FEV1 or BMI (r = 0.25, -0.05). Twenty-eight of 38 children 20 
completed a second CPET the following year with 71 % showing a decline in VO2peak, 21 
(mean decline of 8 % of predicted value, equivalent to 3.8 ml·kg-1·min-1. 22 
 23 
 24 
Conclusion 1 
CPET is feasible with 95 % of children achieving technically satisfactory assessments 2 
starting from age 7. In this group of children with relatively mild CF, mean VO2peak 3 
was normal with no significant correlation between VO2peak and FEV1 or BMI, as 4 
markers of disease severity. The majority of children demonstrated a normal VO2peak. 5 
However, 71 % showed a downward trend on repeat testing 12-18 months later. 6 
 7 
What is already known on this topic 8 
x Exercise testing is not widely used in CF centres in the UK. 9 
x VO2peak and FEV1 are independent predictors of mortality in Cystic Fibrosis. 10 
 11 
What this study adds 12 
x We demonstrate that it is feasible to include a CPET as part of annual review 13 
in children from 7 years and upwards. 14 
x CPET provides information additional to pulmonary function tests. 15 
x In milder disease there is no significant correlation between FEV1 and aerobic 16 
capacity. 17 
x Annual review assessments of exercise capacity may identify declining levels 18 
of fitness and allow early physiotherapy intervention. 19 
 20 
 21 
 22 
 23 
24 
INTRODUCTION 1 
 2 
Objective assessment and monitoring of lung health in Cystic Fibrosis (CF) has 3 
traditionally relied on radiographic and pulmonary function measures. In CF, 4 
pulmonary function, commonly measured as FEV1, was noted to be a strong 5 
prognostic indicator of mortality,[1]. However, with advances in care, abnormal 6 
spirometry is becoming a later disease marker with UK registry data showing that 7 
median (IQR) % predicted FEV1 in children > 6 years attending UK paediatric CF 8 
centres is 86 % predicted (73-97 %),[2]. Nixon et al in 1992, Pianosi et al in 2005 and 9 
more recently, Hulzebos in 2015, showed that aerobic fitness is an independent 10 
predictor of mortality and morbidity in patients with CF,[3,4 5]. 11 
 12 
The UK CF trust guidelines recommend exercise testing at the CF annual review 13 
when clinically indicated,[6]. Additionally, the European Cystic Fibrosis Exercise 14 
Working Group recommend that full CPET should be performed routinely in children 15 
aged 10 years and over,[7]. However, it has been reported that exercise testing is 16 
underused in CF centres in the UK. Of the tests reported to be used, field based 17 
walking tests such as the six-minute self-paced walking test (6MWT) and incremental 18 
shuttle walk test were most common,[8]. To the best of our knowledge there are no 19 
studies assessing the prognostic value of the 6MWT in children with CF. Indeed, 20 
there are limited reports on its prognostic value in adults with CF; for example, 21 
DĂƌƚŝŶĞƚĂƚĨŽƵŶĚƚŚĂƚĂƌĞĚƵĐĞĚ ?ŵŝŶƵƚĞǁĂůŬŝŶŐĚŝƐƚĂŶĐĞŽĨч ? ? ?ŵĂŶĚ22 
ĚĞƐĂƚƵƌĂƚŝŽŶƚŽ^ƉK ?ч ? ?йĚƵring the test were independent predictors of death 23 
without transplantation,[9]. An incremental shuttle test is a reproducible and valid 24 
alternative to CPET,[10] but there have been no studies to investigate its prognostic 1 
value in children with CF. The use of other exercise tests in predicting mortality in 2 
children has been investigated. Aurora et al reported that a low minimum oxygen 3 
saturation (Sa,O2min) during a 12-minute walk test was a poor predictor of mortality 4 
in 181 children with severe CF lung disease referred for lung transplantation,[11]. In 5 
contrast, VO2peak during CPET has been shown to predict mortality in children with 6 
CF,[3,4]. 7 
VO2peak represents the maximal amount of oxygen that can be delivered by the 8 
ĐĂƌĚŝŽǀĂƐĐƵůĂƌƐǇƐƚĞŵĂŶĚƵƚŝůŝƐĞĚĂƚƚŚĞŵƵƐĐůĞƐ ?ƚŚĞƌĞĨŽƌĞĚĞĨŝŶĞƐĂƉĞƌƐŽŶ ?Ɛ9 
functional aerobic capacity,[12]. The correlation between exercise limitation 10 
assessed by VO2peak and lung high resolution computed tomographic (HRCT) 11 
abnormalities has been reported to be stronger than that between spirometry, or 12 
BMI and exercise limitation,[13].In view of the potential usefulness of measuring 13 
VO2peak as a guide to understanding the causes and extent of any exercise limitation 14 
and for guiding the prescription of individualised exercise programmes,[14], our 15 
centre introduced CPET as a replacement to the 6MWT. This has been offered to all 16 
patients aged over 7 years on a yearly basis at their CF annual review from May 17 
2013. Here, we review our experience of measuring VO2peak using CPET in this 18 
context. We were interested to assess whether in clinical use, there were 19 
correlations with other more commonly used outcome measures such as pulmonary 20 
function test result and/or nutritional status measured as BMI. We also investigated 21 
whether there was a difference in mean VO2peak depending on sex, the presence of at 22 
least one DF508 mutation and a history of intravenous antibiotic treatment in the 23 
preceding year. Finally, we were interested to investigate whether there were 1 
annual changes in aerobic capacity over time.  2 
 3 
MATERIALS AND METHODS 4 
Study participants 5 
We retrospectively analysed 18 months of data for each child attending the CF clinic 6 
at the Royal Hospital for Sick Children in Glasgow, who performed CPET between 7 
May 2013 to April 2016. The study cohort comprised of children over 7 years who 8 
regularly attended the CF clinic and who had completed at least one CPET. They all 9 
were clinically stable at the time of testing with disease severities ranging from mild 10 
through to severe. Treatment routines remained unchanged during the study period.  11 
 12 
Anthropometry  13 
Before CPET, height was recorded without shoes to the nearest 0.1 cm using a fixed 14 
stadiometer (Holtan Limited UK),[15]. Weight was measured with minimal clothing 15 
to the nearest 0.1 kg (Seca 704). 16 
 17 
Pulmonary function testing 18 
Before CPET, spirometry and lung volumes were measured using a Jaeger 19 
Masterscreen Body Plethysmograph (Jaeger V5.4, Germany). All pulmonary function 20 
measurements were carried out by an experienced physiologist according to 21 
American Thoracic Society (ATS)/European Respiratory Society (ERS) 22 
standards,[16,17,18]. 23 
Cardiopulmonary Exercise Testing  1 
A symptom limited CPET was performed using an electronically-braked cycle 2 
ergometer (Ergoline, Netherlands) with an incremental ramp protocol. Before each 3 
test, the metabolic cart (Jaeger, CPX, Germany) was calibrated following the 4 
ŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐƉƌŽƚŽĐŽůƵƐŝŶŐŐĂƐĞƐŽĨŬŶŽǁŶĐŽŶĐĞŶƚƌĂƚŝŽŶ ?ĂŶĚan automatic 5 
volume calibration was performed on the turbine volume transducer. We used a 6 
Godfrey exercise protocol,[19] modified by our centre to minimise large increments 7 
in work load. The bicycle ramp ranged between 6.5  W 25 Watts·min-1 with fixed 8 
increments of 6.5, 7.5, 8.5, 10, 12, 15, 20 and 25 Watts·min-1. The ramp was 9 
increased every 10 s to minimise load perception for the patient. To achieve an 10 
optimal test duration of 8- ? ?ŵŝŶ ?ƚŚĞĐŚŝůĚ ?ƐƉƌĞĚŝĐƚĞĚƉŽǁĞƌŽƵƚƉƵƚďĂƐĞĚŽŶ11 
weight,[20] was divided by 10 to give the rate of ramp increase. Patients received 12 
verbal encouragement to achieve as near to a maximal test as possible. The test was 13 
stopped once the cadence could not be maintained > 60 rpm and the patient could 14 
not be verbally encouraged to do so.  VO2peak, peak oxygen pulse (VO2/HRpeak) and 15 
peak ventilation (VEpeak) were averaged over the last 30 s of the test. The gas 16 
exchange threshold was non-ŝŶǀĂƐŝǀĞůǇŝĚĞŶƚŝĨŝĞĚƵƐŝŶŐĂĐŽŵďŝŶĂƚŝŽŶŽĨƚŚĞ ‘s17 
ƐůŽƉĞ ?ŵĞƚŚŽĚĂŶĚǀĞŶƚŝůĂƚŽƌǇĞƋƵivalents,[12]. 18 
 19 
We considered a CPET technically satisfactory if one of the following 3 criteria were 20 
achieved at the end of the test: (1) HRpeak within 15 bpm of predicted maximum 21 
based on age; (2) respiratory exchange ratio (RER) > 1.1; or (3) plateau in VO2. 22 
 23 
 24 
Consent 1 
This study was a retrospective review of results from our standard clinical practice. 2 
As such, we did not seek informed consent for review of the data. All patient data 3 
were anonymised. 4 
 5 
Statistical Analysis 6 
Demographic data (age, sex, genotype and intravenous antibiotic use) were 7 
retrieved from case notes and our CF database and were expressed as means and 8 
standard deviations. FEV1 was expressed in absolute terms and as z-scores using all 9 
age reference ranges,[21]. Static lung volumes were expressed in absolute values 10 
and as z-scores using UK derived paediatric reference ranges,[22]. VO2peak was 11 
expressed in L·min-1, ml·kg-1·min-1and as percent predicted using a paediatric 12 
reference range,[20]. 13 
 14 
The relation between disease severity and VO2peak was assessed in two ways. We 15 
assessed the relation between VO2peak and body mass index (BMI) since it is well 16 
recognized that poor nutritional status has a negative impact on pulmonary 17 
disease,[23,24]. We also examined whether there was a correlation between VO2peak 18 
and intravenous antibiotic use in the preceding year. We included children treated 19 
both for CF exacerbations as well as those receiving routine treatment as part of 20 
their CF management.  21 
 22 
Relationships between VO2peak with FEV1, BMI z-score and age were studied using 23 
WĞĂƌƐŽŶ ?ƐŽƌƌĞůĂƚŝŽŶŽĞĨĨŝĐŝĞŶƚ ?Differences between mean VO2peak with sex and 24 
intravenous antibiotic use were studied using a Two-sample T-Test. A one-way 1 
ANOVA was conducted to compare the effect of genotype (DF508 homozygous, 2 
& ? ? ?ŚĞƚĞƌŽǌǇŐŽƵƐĂŶĚ ‘ŽƚŚĞƌ ?ŐĞŶŽƚǇƉĞƐ ? on VO2peak.  3 
 4 
We used a paired T-test to check for statistically significant differences between 5 
initial and consecutive CPET parameters of aerobic fitness. This included absolute 6 
VO2peak (L·min-1), relative VO2peak (ml·kg-1·min-1), VO2peak % predicted and finally 7 
VO2peak allometrically scaled (ml·kg2/3·min-1). 8 
 9 
RESULTS 10 
Genotype. 11 
Nineteen children with DF508 homozygous, 16 children DF508 heterozygous and 3 12 
ĐŚŝůĚƌĞŶǁŝƚŚ ‘ŽƚŚĞƌ ?ŐĞŶŽƚǇƉĞƐ ? 13 
 14 
Pulmonary function & anthropometry. 15 
Anthropometry and pulmonary function are summarised in tables 1 & 2. We 16 
analysed results from 38 children (17 male and 21 female). Seven children had an 17 
FEV1 consistently below the lower limit of normal,[22].  18 
 19 
Table 1  20 
 21 
Table 2  22 
 23 
CPET parameters are summarised in table 3. We were able to perform technically 1 
satisfactory assessments on 36/38 (95 %) of children.  In 2 young children (both 7 2 
years old) the CPET was technically unsatisfactory due to poor cooperation and 3 
effort. Aerobic capacity in children with CF was within a range consistent with a 4 
normal, healthy population (VO2peak ŽĨш ? ?йƉƌĞĚŝĐƚĞĚ ? ?25]). Only 5 children (13 %) 5 
had VO2peak of < 85 % predicted. Two children desaturated to SpO2 < 95 % at peak 6 
exercise. No ECG arrhythmias were detected in any of the patients. 7 
 8 
Table 3 9 
 10 
hƐŝŶŐWĞĂƌƐŽŶ ?ƐŽƌƌĞůĂƚŝŽŶŽĞĨĨŝĐŝĞŶƚ ?ǁĞĨŽƵŶĚŶŽƐŝŐŶŝĨŝĐĂŶƚĐŽƌƌĞůĂƚŝŽŶďĞƚǁĞĞŶ11 
VO2peak and FEV1 (r =0.25, p=0.13), VO2peak and age (r =-0.24, p=0.15) or between 12 
VO2peak and BMI z-score (r =-0.05, p=0.77).  Using a Two-sample T-Test, we found no 13 
significant differences in mean VO2peak between males (107.9±19.1) vs females 14 
(107.1±17.0), p=0.90. Fourteen of 38 child received intravenous antibiotic treatment 15 
in the preceding year. We found no significant differences in mean VO2peak if the 16 
child had received intravenous antibiotics (103.0±18.5) vs no intravenous antibiotics 17 
(110.1±17.1), p=0.23. Nineteen children were DF508 homozygous, 16 were DF508 18 
ŚĞƚĞƌŽǌǇŐŽƵƐĂŶĚ ?ŚĂĚ ‘ŽƚŚĞƌ ?ŐĞŶŽƚǇƉĞƐ ?tĞĨŽƵŶĚŶŽƐŝŐŶŝĨŝĐĂŶƚ effect of 19 
genotype on VO2peak (p=0.24). 20 
 21 
Figure 1. Change in VO2peak % predicted in 28 children with CF measured between 12-22 
18 months apart 23 
 24 
Consecutive annual CPET data were available for 28/38 (74 %) children (Figure 1). 1 
These were performed up to 18 months after the initial CPET due to timings of the 2 
CF annual review appointment. Ten children did not perform a repeat CPET: 3 3 
transitioned to adult services; 4 did not attend their annual review appointment; 1 4 
had a CF exacerbation at the time of annual review; 1 had an unsatisfactory test due 5 
to submaximal patient effort and there was insufficient staffing for 1 patient. 6 
 7 
VO2peak decreased in 71 % of the subjects. The mean change in VO2peak parameters 8 
are shown in table 4. Overall, there was no significant difference in mean change of 9 
absolute VO2peak (p > 0.05). However, there was a statistically significant decline in 10 
VO2peak when it was related to body weight, or to % predicted VO2peak (which includes 11 
sex and body weight in the predicting equation) or when using allometrical scaling 12 
(ml·kg-2/3·min-1), p= 0.001, 0.003 and 0.03 respectively. The mean decline relative to 13 
body weight was 3.8 ml·kg-1·min-1equivalent to an 8 % from baseline value.  An 8% 14 
change is greater than the normal coefficient of variation reported in the literature 15 
for VO2peak (4.8%) when looking at biological quality control,[26] although the normal 16 
variability for young CF patients is likely to be greater,[27].  17 
18 
DISCUSSION 1 
We found that the majority of our CF patients had normal BMI and pulmonary 2 
function in keeping with data in the UK CF registry,[2]. In this relatively mild group of 3 
children with CF, the majority of our VO2peak results were also normal suggesting that 4 
we have an aerobically fit group of children. This may partly refůĞĐƚŽƵƌĞŶƚƌĞ ?Ɛ5 
focus on promoting a healthy diet, regular physical activity and physiotherapy in our 6 
CF patients.   7 
 8 
We found no significant correlation between FEV1 and VO2peak. This could be 9 
explained by the relatively small sample size and the majority having normal lung 10 
function and aerobic capacity. However, it is also recognized that FEV1 has to be 11 
significantly reduced to affect exercise capacity,[28]. Previously, FEV1 has been 12 
shown to correlate with VO2peak in children,[29]. McBride et al investigated 64 13 
children with CF aged 8-11 years and found a statistically significant but weak 14 
correlation between FEV1 % predicted and VO2peak % predicted with an R2 value of 15 
0.14. The most likely explanation for the differences observed in our study is a 16 
combination of a larger sample with a wider range of lung function and fitness. 17 
However, the low R2 in the study by McBride and the absence of any correlation in 18 
our data suggest there is not a strong relationship between FEV1 and VO2peak. As only 19 
7 of our patients had an FEV1 below the lower limit of normal, it is perhaps not 20 
surprising that we did not see a relationship in a relatively mildly affected 21 
population,[30]. However, there is also a debate about the factors which limit 22 
aerobic function in CF with both suggestions of central such as impaired stroke 23 
volume,[31]  and/or peripheral mechanisms such as impaired muscle metabolism 1 
being involved, apart from changes in lung function[32]. 2 
 3 
In our mild to moderate CF children, the majority did not demonstrate any evidence 4 
of ventilation limitation at maximal exercise, as would be expected in healthy 5 
children. There are varying reports in the literature on the aerobic fitness of CF 6 
children. Nixon et al were one of the first groups to investigate VO2peak and its 7 
prognostic value. Their group included 40 adults and 68 children and adolescents. 8 
They found a range of lung function impairment with 65 % of their study population 9 
having an FEV1 of < 65 % predicted. They found generally a low aerobic capacity with 10 
a mean VO2peak of 70 % predicted (35 ml·kg-1·min-1),[3]. More recently, Hulzebos et al 11 
investigated 127 adolescents with CF with a mean FEV1 of 77.7±15.6 % predicted and 12 
a VO2peak/kg 93.3±17.9 % predicted,[5].  13 
 14 
Pianosi et al exclusively investigated children with CF and reported an initial VO2peak 15 
of 41.2 ml·kg-1·min-1,[4]. dŚŝƐǁŽƵůĚďĞĐůĂƐƐĞĚĂƐ ‘ĨĂŝƌ ?ĂĞƌŽďŝĐĨŝƚŶĞƐƐĂĐĐŽƌĚŝŶŐƚŽ16 
published reference values for children and adolescents,[28]. More recent studies 17 
have included control groups and showed that CF children and adolescents had a 18 
significantly reduced VO2peak when compared to healthy children. For example, 19 
Bongers et al found their CF group of 22 children was within the normal range 20 
although the values for VO2peak were significantly lower than the controls,[33]. 21 
Saynor et al also found a reduced aerobic capacity (mean VO2peak 36.3 ml·kg-1·min-1) 22 
in subjects with CF compared to controls,[34].  23 
Other studies have reported that nutritional status affects exercise capacity,[35,36] 1 
but since very few of the children in our study had either an abnormal BMI or an 2 
abnormal VO2peak ч ? ?йƉƌĞĚŝĐƚĞĚ ?ƌĂŶŐĞ ? ? W 84),[25] we were unable to 3 
demonstrate a significant a correlation. On reviewing the 3 children with an 4 
abnormal VO2peak, all had normal BMI z-scores -0.57, 1.13, 1.83. One child with a BMI 5 
z-score of 1.83 (98th percentile) and VO2peak 74 % predicted, had poor exercise 6 
activity. His low VO2peak may be a reflection of deconditioning as well as high fat 7 
rather than muscle mass.  8 
 9 
Whilst the majority of our patients had normal CPET results, 71 % demonstrated a 10 
decline in VO2peak on repeat testing 12- 18 months later. There is little reported data 11 
about what constitutes a significant decline in VO2peak in CF patients. There are a 12 
number of cross sectional and longitudinal studies investigating the trend in VO2peak 13 
in healthy children. In a review by Krahenbhul et al, mean values of VO2peak relative 14 
to body weight from several longitudinal and cross sectional studies were plotted 15 
against age in males and females to investigate the relationship over the age range 16 
6-16 years,[37]. They found that males had an unchanged VO2peak corrected for body 17 
weight over time, whereas females showed a decline from 52.0 ml·kg-1·min-1to 40.5 18 
ml·kg-1·min-1. However, it is recognized that correcting VO2peak for body mass has 19 
limitations and does not normalize the data,[38,39]. Ratio scaling of VO2peak by body 20 
mass (as opposed to fat free mass) penalizes females and those that are heavier than 21 
their aged match peers and it has been reported that allometric scaling of VO2peak is a 22 
more reliable method to interpret changes in VO2peak,[40]. The Amsterdam Growth 23 
and Health Longitudinal Study recently published data on changes in aerobic fitness 24 
for approximately 650 adolescents over a 25 year period. VO2peak was presented in 1 
absolute values, relative to body weight and allometrically scaled. They found that 2 
from 12-17 years in both males and females, there was a downward trend in VO2peak 3 
relative to body weight.  However, when allometrically scaled, VO2peak in males did 4 
not decrease whereas females did demonstrate a decline,[41].  In our data, aerobic 5 
fitness declined significantly, irrespective of whether it was related to body weight, 6 
or to sex and body weight using the predicted values or using allometric scaling 7 
(table 4), although the deterioration was least using allometric scaling.   8 
 9 
Pianosi et al looked at annual CPET over a 5 year period in CF children and found that 10 
VO2peak decreased in 70 % of the subjects with a mean annual decline of 2.1 ml·kg-11 
1·min-1,[4].  These results show similarity to our results, albeit over a much shorter 12 
period. We can only speculate on the reasons for the decline in some children. 13 
Although changes in lung function itself may not have caused changes in aerobic 14 
fitness, acute exacerbations as well as disease progression may have resulted in 15 
these patients participating in less physical activity with a consequent reduction in 16 
fitness. In others, the increase fitness may represent the effects of interventions 17 
such as planned exercise prescription.   18 
 19 
Pianosi also showed that initial VO2peak did not affect the rate of decline and this 20 
highlights that longitudinal assessments of aerobic capacity are important,[4]. 21 
Further work will be required to investigate the place of repeated CPET tests in 22 
assessing exercise capacity in CF patients over time.  Identifying a downward trend in 23 
ĂĐŚŝůĚ ?ƐĞǆĞƌĐŝƐĞĐĂƉĂĐŝƚǇŵĂǇĂůůŽǁĞĂƌůǇƉŚǇƐŝŽƚŚĞƌĂƉǇŝŶƚĞƌǀĞŶƚŝŽŶĂŶĚ24 
encouragement to increase physical activity to prevent ongoing decline in exercise 1 
capacity. ZĞŐĂƌĚůĞƐƐŽĨƚŚĞĚĞĨŝŶŝƚŝŽŶŽĨĂ ‘ĐůŝŶŝĐĂůůǇƐŝŐŶŝĨŝĐĂŶƚĚĞĐůŝŶĞ ?ŝŶsK2peak, we 2 
consider any fall in exercise capacity to be important as small declines in VO2peak may 3 
cumulatively result in a clinically significant reduction in aerobic capacity. Pianosi at 4 
al showed that patients with VO2peak < 32 ml·kg-1·min-1exhibited a dramatic increase 5 
in mortality,[4]. This may highlight those who would benefit from additional 6 
encouragement to increase their physical activity and prevent de-conditioning.   7 
 8 
We had previously used the 6 Minute Walk Test (6MWT) to assess exercise 9 
performance at annual review but in the light of the evidence about VO2peak as a 10 
strong predictor of mortality, we replaced the 6MWT with CPET. Whilst the initial 11 
cost for CPET equipment is significant, the cost for consumables is minimal and our 12 
respiratory laboratory already had dedicated time allocated for the assessments.  13 
Performing an annual CPET in place of 6MWT added minimal time to the CF annual 14 
review visit. We found that it was feasible to include CPET as part of the annual 15 
review. Ninety-five % of our children achieved technically satisfactory assessments 16 
starting from an age of 7 years. In our centre, children under 7 years of age are not 17 
routinely offered CPET or field exercise test due to difficulties in performing them in 18 
this age group. However, we would attempt CPET if clinically indicated and at the 19 
discretion of the referring clinician. For the duration of this study, no children under 20 
7 years of age were referred for exercise testing. Whilst we have demonstrated that 21 
CPET is a feasible and achievable investigation in children 7 years and older at the CF 22 
annual review, it is a technically demanding assessment and can only be performed 23 
in a centre with the necessary equipment and appropriately trained staff.  24 
Although we have no formal feedback, the majority of our patients and their parents 1 
have engaged well with the introduction of CPET at annual reviews. The children 2 
reported that they enjoy the challenge of CPET. Importantly, our respiratory 3 
physiotherapists have found CPET clinically beneficial in identifying those children 4 
needing more specific exercise advice, particularly for children with stable lung 5 
function but declining VO2peak. Of the 5 patients who had an abnormal VO2peak ч ? ?й6 
predicted, none had reduced lung function. Whilst our centre encourages all our 7 
patients to undergo regular physical activity, the declines in VO2peak highlighted the 8 
need for additional physiotherapy intervention to increase their physical activity and 9 
prevent ongoing decline. This emphasizes the value of using CPET as an assessment 10 
tool to guide counseling about exercise and the prescription and monitoring of 11 
exercise programmes,[42].  12 
 13 
Study limitations 14 
This was a retrospective review and we had no control group, relying instead on 15 
published normal data. We recognise that our numbers were small, only 74 % 16 
completed a second CPET during the study period, and our patients were only 17 
followed up for one year.  We continue to collect data as longer follow up will give a 18 
more informative assessment of extent and value of changes in aerobic capacity. In 19 
this case, the predicted values for VO2peak are based on a limited number of North 20 
American children. Future research should focus on providing suitable reference 21 
data for UK children. In the context of our paediatric clinical population, it was not 22 
ĨĞĂƐŝďůĞƚŽƉĞƌĨŽƌŵĂƐƵƉƌĂŵĂǆŝŵĂůƚĞƐƚŽŶĞĂĐŚƉĂƚŝĞŶƚƚŽǀĞƌŝĨǇĂ ‘ƚƌƵĞ ?sK2peak as 23 
demonstrated by a plateau in VO2. Our use of secondary criteria of HRpeak and RER 24 
ŵĂǇƚŚĞƌĞĨŽƌĞƵŶĚĞƌĞƐƚŝŵĂƚĞƚŚĞ ‘ƚƌƵĞ ?sK2peak,[43].  We also did not routinely take 1 
body fat measurements but recognise that this may affect the VO2peak % predicted 2 
which uses body weight in the predictive equation. Finally, we had no standardised 3 
recording of physical activity levels of the children in the 12-18 month interval 4 
between the first and second tests which might have been informative in assessing 5 
the effect of regular activity and/or exercise on aerobic capacity.  6 
 7 
CONCLUSION 8 
CPET is feasible as a test of aerobic function at the CF annual review. It offers 9 
additional prognostic information to routine pulmonary function tests and allows 10 
identification of de-conditioned patients who may need to increase their physical 11 
activity. In our population with relatively mild CF, most children had normal VO2peak 12 
when compared with reference data. However, a large majority showed significant 13 
declines in VO2peak the following year highlighting the importance of serial aerobic 14 
fitness measurements to help identify patients who may benefit from additional 15 
physiotherapy support and intervention. 16 
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Table 1  
 
Variable  mean SD 
Min, max 
Range 
Age (years) 11.0 2.39 7.3, 15.7 
Height (cm) 145.3 16.48 115, 180.8 
Body mass (kg) 39.2 13.18 20.2, 69.5 
BMI z-score 0.1 1.00 -2.2, 2.5 
 
Table 2  
 
Variable  mean SD 
Min, max 
Range 
FEV1 (L) 2.07 0.75 0.98, 4.06 
FEV1 z-score -0.77 1.24 -4.42, 2.24 
FEV1/FVC (%) 81 8 57, 96 
FEV1/FVC (%) z-score -0.99 1.24 -3.64, 1.55 
TLC (L) 3.67 1.15 2.04, 7.01 
TLC z-score 0.70 1.04 -1.08, 3.17 
RV (L) 1.07 0.49 0.58, 2.58 
RV z-score 0.59 1.75 -1.48, 6.61 
 
Table 3 
 
Variable Mean SD 
Min, Max 
Range 
Maximal Exercise parameters       
Absolute VO2peak (L·min-1) 1.58 0.52 0.88, 3.01 
Relative VO2peak (ml·kg-1·min-1)  42.0 7.7 29.2, 62.3 
VO2peak (% predicted) 105 18 74, 150 
VE max (L·min-1) 64 24 28, 137 
Breathing reserve (%) 19 20 -36, 54 
Heart Rate max (Beats·min-1) 188 10 160, 208 
Oxygen Pulse max (ml·beat-1) 8.6 2.8 4.0, 16.0 
End test SpO2 (%) 97 2 89, 100 
Peak power Output (Watt) 97 42 41, 212 
Relative Peak power output Watt·kg-1) 2.5 0.6 1.6, 3.8 
    
Submaximal Exercise    
VO2 at GET (ml·min-1) 826 215 415, 1455 
GET (% of VO2peak) 53 7 38, 70 
VO2/Work Rate (ml·watt-1·min-1) 10.6 0.9 9.1, 12.3 
VE/VCO2 Slope 30.9 3.8 22.4, 44.0 
  GET - Gas exchange Threshold 
 
 
 
 
 
 
                                                                                                                                            
 
 
 
 
 
 
 
Table 4 
Variable Mean1st CPET Mean2nd CPET 
Absolute 
Difference % Difference 
VO2peak (L·min-1) 1525 ± 480 1539 ± 420 14 1 
VO2peak Relative to bodyweight  
(ml·kg-1·min-1) 
42.7 ± 7.0 38.9 ± 8.2 -3.8 -9 
VO2peak % Predicted  
(includes sex and body weight) 
107 ± 17 99 ± 17 -8 -8 
VO2peak Allometrically scaled  
(ml·kg-2/3·min-1) 
137 ± 22 130 ± 22 -7 -6 
 
